when was semaglutide patented Patent Expiry in 2026: Why India Is On the Pharma Radar Massive Rs 50,000 Cr Opportunity

Start your weight loss journey without delay

Executive summary Among 1,482 adults with a body mass index (BMI) 27 kg/m2 who initiated injectable semaglutide between March 2018 and November 2023, the median percentage BMI reduction after 3-6 months was 4.5% (interquartile range: 1.8% to 8.3%)

Stremmel W, Longerich T, Liere R, Vacata V, van Helden J, Weiskirchen R

2(b)) shows the existence of mutil-layered wsGNS

It is not intended for human consumption, injection, therapeutic use, or diagnostic procedures

On top of this, gut conditions like small intestinal bacterial overgrowth (SIBO), which is more common in women during midlife, can reduce DAO activity further